http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 27 Aug 2026 16:29:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BECTON+DICKINSON+%26amp%3B+CO++For%3A+Aug+26++Filed+by%3A+Feld+Michael/26990425.html si-local-file:///var/storage/secattach/20260827/26990425.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BECTON+DICKINSON+%26amp%3B+CO++For%3A+Aug+26++Filed+by%3A+Feld+Michael/26990425.html Thu, 27 Aug 2026 16:29:00 -0400 BDX O.00000286 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BECTON+DICKINSON+%26amp%3B+CO++For%3A+Aug+26++Filed+by%3A+Feld+Michael/26990425.html si-local-file:///var/storage/secattach/20260827/26990425.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BECTON+DICKINSON+%26amp%3B+CO++For%3A+Aug+26++Filed+by%3A+Feld+Michael/26990425.html Thu, 27 Aug 2026 16:29:00 -0400 BDX O.00000286 http://www.streetinsider.com/Corporate+News/BD+trial+for+breast+implant+revision+surgery+passes+enrollment+milestone/26984438.html <p>Becton, Dickinson and Company (NYSE: BDX) announced that its STANCE clinical trial, evaluating GalaFLEX LITE™ Scaffold in breast revision surgery for capsular contracture, has surpassed its first enrollment milestone, with 274 patients treated across 33 active U.S. sites.</p><p>The milestone triggers the trial's first planned interim analysis and places enrollment beyond 50% of the study's maximum planned total. The adaptive trial design anticipates between 250 and 530 patients in total.</p><p>The STANCE trial (NCT05945329) is a prospective, randomized, controlled, multi-center study assessing the safety and efficacy of GalaFLEX LITE™ Scaffold in revision surgery for reduction of capsular contracture recurrence and implant malposition. http://www.streetinsider.com/Corporate+News/BD+trial+for+breast+implant+revision+surgery+passes+enrollment+milestone/26984438.html Thu, 27 Aug 2026 06:51:35 -0400 BDX http://www.streetinsider.com/Press+Releases/BD+Extends+Leadership+in+Advanced+Tissue+Regeneration+Through+Continued+Clinical+Innovation/26984421.html <div class="xn-content"> <p class="prntac"><i>STANCE trial surpasses a key enrollment milestone, advancing the clinical evaluation of GalaFLEX LITE™ Scaffold and generating evidence to support its use in breast revision surgery for capsular contracture</i></p><p><span class="legendSpanClass"><location value="LU/us.nj.frakes" idsrc="xmltag.org" >FRANKLIN LAKES, N.J.</location></span>, <span class="legendSpanClass"><chron>Aug. 27, 2026</chron></span> /PRNewswire/ -- BD (<span value="NYSE:BDX" idsrc="xmltag.org" >Becton, Dickinson and Company</span>) (NYSE: BDX), a leading global medical technology company, today announced a significant milestone in its advanced tissue regeneration strategy and expansion efforts with the STANCE clinical trial evaluating GalaFLEX LITE™ Scaffold in breast revision surgery for capsular contracture. The study has reached its first enrollment milestone, with 274 patients http://www.streetinsider.com/Press+Releases/BD+Extends+Leadership+in+Advanced+Tissue+Regeneration+Through+Continued+Clinical+Innovation/26984421.html Thu, 27 Aug 2026 06:50:00 -0400 A.01615153 A.06822034 BDX O.00000286 O.01214331 O.20026344 http://www.streetinsider.com/Press+Releases/BD+Extends+Leadership+in+Advanced+Tissue+Regeneration+Through+Continued+Clinical+Innovation/26984421.html <div class="xn-content"> <p class="prntac"><i>STANCE trial surpasses a key enrollment milestone, advancing the clinical evaluation of GalaFLEX LITE™ Scaffold and generating evidence to support its use in breast revision surgery for capsular contracture</i></p><p><span class="legendSpanClass"><location value="LU/us.nj.frakes" idsrc="xmltag.org" >FRANKLIN LAKES, N.J.</location></span>, <span class="legendSpanClass"><chron>Aug. 27, 2026</chron></span> /PRNewswire/ -- BD (<span value="NYSE:BDX" idsrc="xmltag.org" >Becton, Dickinson and Company</span>) (NYSE: BDX), a leading global medical technology company, today announced a significant milestone in its advanced tissue regeneration strategy and expansion efforts with the STANCE clinical trial evaluating GalaFLEX LITE™ Scaffold in breast revision surgery for capsular contracture. The study has reached its first enrollment milestone, with 274 patients http://www.streetinsider.com/Press+Releases/BD+Extends+Leadership+in+Advanced+Tissue+Regeneration+Through+Continued+Clinical+Innovation/26984421.html Thu, 27 Aug 2026 06:50:00 -0400 A.01615153 A.06822034 BDX O.00000286 O.01214331 O.20026344 http://www.streetinsider.com/Press+Releases/BD+Extends+Leadership+in+Advanced+Tissue+Regeneration+Through+Continued+Clinical+Innovation/26984421.html <div class="xn-content"> <p class="prntac"><i>STANCE trial surpasses a key enrollment milestone, advancing the clinical evaluation of GalaFLEX LITE™ Scaffold and generating evidence to support its use in breast revision surgery for capsular contracture</i></p><p><span class="legendSpanClass"><location value="LU/us.nj.frakes" idsrc="xmltag.org" >FRANKLIN LAKES, N.J.</location></span>, <span class="legendSpanClass"><chron>Aug. 27, 2026</chron></span> /PRNewswire/ -- BD (<span value="NYSE:BDX" idsrc="xmltag.org" >Becton, Dickinson and Company</span>) (NYSE: BDX), a leading global medical technology company, today announced a significant milestone in its advanced tissue regeneration strategy and expansion efforts with the STANCE clinical trial evaluating GalaFLEX LITE™ Scaffold in breast revision surgery for capsular contracture. The study has reached its first enrollment milestone, with 274 patients http://www.streetinsider.com/Press+Releases/BD+Extends+Leadership+in+Advanced+Tissue+Regeneration+Through+Continued+Clinical+Innovation/26984421.html Thu, 27 Aug 2026 06:50:00 -0400 A.01615153 A.06822034 BDX O.00000286 O.01214331 O.20026344 http://www.streetinsider.com/Press+Releases/BD+Extends+Leadership+in+Advanced+Tissue+Regeneration+Through+Continued+Clinical+Innovation/26984421.html <div class="xn-content"> <p class="prntac"><i>STANCE trial surpasses a key enrollment milestone, advancing the clinical evaluation of GalaFLEX LITE™ Scaffold and generating evidence to support its use in breast revision surgery for capsular contracture</i></p><p><span class="legendSpanClass"><location value="LU/us.nj.frakes" idsrc="xmltag.org" >FRANKLIN LAKES, N.J.</location></span>, <span class="legendSpanClass"><chron>Aug. 27, 2026</chron></span> /PRNewswire/ -- BD (<span value="NYSE:BDX" idsrc="xmltag.org" >Becton, Dickinson and Company</span>) (NYSE: BDX), a leading global medical technology company, today announced a significant milestone in its advanced tissue regeneration strategy and expansion efforts with the STANCE clinical trial evaluating GalaFLEX LITE™ Scaffold in breast revision surgery for capsular contracture. The study has reached its first enrollment milestone, with 274 patients http://www.streetinsider.com/Press+Releases/BD+Extends+Leadership+in+Advanced+Tissue+Regeneration+Through+Continued+Clinical+Innovation/26984421.html Thu, 27 Aug 2026 06:50:00 -0400 A.01615153 A.06822034 BDX O.00000286 O.01214331 O.20026344 http://www.streetinsider.com/Press+Releases/BD+Extends+Leadership+in+Advanced+Tissue+Regeneration+Through+Continued+Clinical+Innovation/26984421.html <div class="xn-content"> <p class="prntac"><i>STANCE trial surpasses a key enrollment milestone, advancing the clinical evaluation of GalaFLEX LITE™ Scaffold and generating evidence to support its use in breast revision surgery for capsular contracture</i></p><p><span class="legendSpanClass"><location value="LU/us.nj.frakes" idsrc="xmltag.org" >FRANKLIN LAKES, N.J.</location></span>, <span class="legendSpanClass"><chron>Aug. 27, 2026</chron></span> /PRNewswire/ -- BD (<span value="NYSE:BDX" idsrc="xmltag.org" >Becton, Dickinson and Company</span>) (NYSE: BDX), a leading global medical technology company, today announced a significant milestone in its advanced tissue regeneration strategy and expansion efforts with the STANCE clinical trial evaluating GalaFLEX LITE™ Scaffold in breast revision surgery for capsular contracture. The study has reached its first enrollment milestone, with 274 patients http://www.streetinsider.com/Press+Releases/BD+Extends+Leadership+in+Advanced+Tissue+Regeneration+Through+Continued+Clinical+Innovation/26984421.html Thu, 27 Aug 2026 06:50:00 -0400 A.01615153 A.06822034 BDX O.00000286 O.01214331 O.20026344 http://www.streetinsider.com/Press+Releases/BD+Extends+Leadership+in+Advanced+Tissue+Regeneration+Through+Continued+Clinical+Innovation/26984421.html <div class="xn-content"> <p class="prntac"><i>STANCE trial surpasses a key enrollment milestone, advancing the clinical evaluation of GalaFLEX LITE™ Scaffold and generating evidence to support its use in breast revision surgery for capsular contracture</i></p><p><span class="legendSpanClass"><location value="LU/us.nj.frakes" idsrc="xmltag.org" >FRANKLIN LAKES, N.J.</location></span>, <span class="legendSpanClass"><chron>Aug. 27, 2026</chron></span> /PRNewswire/ -- BD (<span value="NYSE:BDX" idsrc="xmltag.org" >Becton, Dickinson and Company</span>) (NYSE: BDX), a leading global medical technology company, today announced a significant milestone in its advanced tissue regeneration strategy and expansion efforts with the STANCE clinical trial evaluating GalaFLEX LITE™ Scaffold in breast revision surgery for capsular contracture. The study has reached its first enrollment milestone, with 274 patients http://www.streetinsider.com/Press+Releases/BD+Extends+Leadership+in+Advanced+Tissue+Regeneration+Through+Continued+Clinical+Innovation/26984421.html Thu, 27 Aug 2026 06:50:00 -0400 A.01615153 A.06822034 BDX O.00000286 O.01214331 O.20026344 http://www.streetinsider.com/PRNewswire/BD+Extends+Leadership+in+Advanced+Tissue+Regeneration+Through+Continued+Clinical+Innovation/26984421.html <div class="xn-content"> <p class="prntac"><i>STANCE trial surpasses a key enrollment milestone, advancing the clinical evaluation of GalaFLEX LITE™ Scaffold and generating evidence to support its use in breast revision surgery for capsular contracture</i></p><p><span class="legendSpanClass"><location value="LU/us.nj.frakes" idsrc="xmltag.org" >FRANKLIN LAKES, N.J.</location></span>, <span class="legendSpanClass"><chron>Aug. 27, 2026</chron></span> /PRNewswire/ -- BD (<span value="NYSE:BDX" idsrc="xmltag.org" >Becton, Dickinson and Company</span>) (NYSE: BDX), a leading global medical technology company, today announced a significant milestone in its advanced tissue regeneration strategy and expansion efforts with the STANCE clinical trial evaluating GalaFLEX LITE™ Scaffold in breast revision surgery for capsular contracture. The study has reached its first enrollment milestone, with 274 patients http://www.streetinsider.com/PRNewswire/BD+Extends+Leadership+in+Advanced+Tissue+Regeneration+Through+Continued+Clinical+Innovation/26984421.html Thu, 27 Aug 2026 06:50:00 -0400 A.01615153 A.06822034 BDX O.00000286 O.01214331 O.20026344 http://www.streetinsider.com/PRNewswire/BD+Extends+Leadership+in+Advanced+Tissue+Regeneration+Through+Continued+Clinical+Innovation/26984421.html <div class="xn-content"> <p class="prntac"><i>STANCE trial surpasses a key enrollment milestone, advancing the clinical evaluation of GalaFLEX LITE™ Scaffold and generating evidence to support its use in breast revision surgery for capsular contracture</i></p><p><span class="legendSpanClass"><location value="LU/us.nj.frakes" idsrc="xmltag.org" >FRANKLIN LAKES, N.J.</location></span>, <span class="legendSpanClass"><chron>Aug. 27, 2026</chron></span> /PRNewswire/ -- BD (<span value="NYSE:BDX" idsrc="xmltag.org" >Becton, Dickinson and Company</span>) (NYSE: BDX), a leading global medical technology company, today announced a significant milestone in its advanced tissue regeneration strategy and expansion efforts with the STANCE clinical trial evaluating GalaFLEX LITE™ Scaffold in breast revision surgery for capsular contracture. The study has reached its first enrollment milestone, with 274 patients http://www.streetinsider.com/PRNewswire/BD+Extends+Leadership+in+Advanced+Tissue+Regeneration+Through+Continued+Clinical+Innovation/26984421.html Thu, 27 Aug 2026 06:50:00 -0400 A.01615153 A.06822034 BDX O.00000286 O.01214331 O.20026344 http://www.streetinsider.com/PRNewswire/BD+Extends+Leadership+in+Advanced+Tissue+Regeneration+Through+Continued+Clinical+Innovation/26984421.html <div class="xn-content"> <p class="prntac"><i>STANCE trial surpasses a key enrollment milestone, advancing the clinical evaluation of GalaFLEX LITE™ Scaffold and generating evidence to support its use in breast revision surgery for capsular contracture</i></p><p><span class="legendSpanClass"><location value="LU/us.nj.frakes" idsrc="xmltag.org" >FRANKLIN LAKES, N.J.</location></span>, <span class="legendSpanClass"><chron>Aug. 27, 2026</chron></span> /PRNewswire/ -- BD (<span value="NYSE:BDX" idsrc="xmltag.org" >Becton, Dickinson and Company</span>) (NYSE: BDX), a leading global medical technology company, today announced a significant milestone in its advanced tissue regeneration strategy and expansion efforts with the STANCE clinical trial evaluating GalaFLEX LITE™ Scaffold in breast revision surgery for capsular contracture. The study has reached its first enrollment milestone, with 274 patients http://www.streetinsider.com/PRNewswire/BD+Extends+Leadership+in+Advanced+Tissue+Regeneration+Through+Continued+Clinical+Innovation/26984421.html Thu, 27 Aug 2026 06:50:00 -0400 A.01615153 A.06822034 BDX O.00000286 O.01214331 O.20026344 http://www.streetinsider.com/PRNewswire/BD+Extends+Leadership+in+Advanced+Tissue+Regeneration+Through+Continued+Clinical+Innovation/26984421.html <div class="xn-content"> <p class="prntac"><i>STANCE trial surpasses a key enrollment milestone, advancing the clinical evaluation of GalaFLEX LITE™ Scaffold and generating evidence to support its use in breast revision surgery for capsular contracture</i></p><p><span class="legendSpanClass"><location value="LU/us.nj.frakes" idsrc="xmltag.org" >FRANKLIN LAKES, N.J.</location></span>, <span class="legendSpanClass"><chron>Aug. 27, 2026</chron></span> /PRNewswire/ -- BD (<span value="NYSE:BDX" idsrc="xmltag.org" >Becton, Dickinson and Company</span>) (NYSE: BDX), a leading global medical technology company, today announced a significant milestone in its advanced tissue regeneration strategy and expansion efforts with the STANCE clinical trial evaluating GalaFLEX LITE™ Scaffold in breast revision surgery for capsular contracture. The study has reached its first enrollment milestone, with 274 patients http://www.streetinsider.com/PRNewswire/BD+Extends+Leadership+in+Advanced+Tissue+Regeneration+Through+Continued+Clinical+Innovation/26984421.html Thu, 27 Aug 2026 06:50:00 -0400 A.01615153 A.06822034 BDX O.00000286 O.01214331 O.20026344 http://www.streetinsider.com/PRNewswire/BD+Extends+Leadership+in+Advanced+Tissue+Regeneration+Through+Continued+Clinical+Innovation/26984421.html <div class="xn-content"> <p class="prntac"><i>STANCE trial surpasses a key enrollment milestone, advancing the clinical evaluation of GalaFLEX LITE™ Scaffold and generating evidence to support its use in breast revision surgery for capsular contracture</i></p><p><span class="legendSpanClass"><location value="LU/us.nj.frakes" idsrc="xmltag.org" >FRANKLIN LAKES, N.J.</location></span>, <span class="legendSpanClass"><chron>Aug. 27, 2026</chron></span> /PRNewswire/ -- BD (<span value="NYSE:BDX" idsrc="xmltag.org" >Becton, Dickinson and Company</span>) (NYSE: BDX), a leading global medical technology company, today announced a significant milestone in its advanced tissue regeneration strategy and expansion efforts with the STANCE clinical trial evaluating GalaFLEX LITE™ Scaffold in breast revision surgery for capsular contracture. The study has reached its first enrollment milestone, with 274 patients http://www.streetinsider.com/PRNewswire/BD+Extends+Leadership+in+Advanced+Tissue+Regeneration+Through+Continued+Clinical+Innovation/26984421.html Thu, 27 Aug 2026 06:50:00 -0400 A.01615153 A.06822034 BDX O.00000286 O.01214331 O.20026344 http://www.streetinsider.com/PRNewswire/BD+Extends+Leadership+in+Advanced+Tissue+Regeneration+Through+Continued+Clinical+Innovation/26984421.html <div class="xn-content"> <p class="prntac"><i>STANCE trial surpasses a key enrollment milestone, advancing the clinical evaluation of GalaFLEX LITE™ Scaffold and generating evidence to support its use in breast revision surgery for capsular contracture</i></p><p><span class="legendSpanClass"><location value="LU/us.nj.frakes" idsrc="xmltag.org" >FRANKLIN LAKES, N.J.</location></span>, <span class="legendSpanClass"><chron>Aug. 27, 2026</chron></span> /PRNewswire/ -- BD (<span value="NYSE:BDX" idsrc="xmltag.org" >Becton, Dickinson and Company</span>) (NYSE: BDX), a leading global medical technology company, today announced a significant milestone in its advanced tissue regeneration strategy and expansion efforts with the STANCE clinical trial evaluating GalaFLEX LITE™ Scaffold in breast revision surgery for capsular contracture. The study has reached its first enrollment milestone, with 274 patients http://www.streetinsider.com/PRNewswire/BD+Extends+Leadership+in+Advanced+Tissue+Regeneration+Through+Continued+Clinical+Innovation/26984421.html Thu, 27 Aug 2026 06:50:00 -0400 A.01615153 A.06822034 BDX O.00000286 O.01214331 O.20026344 http://www.streetinsider.com/SEC+Filings/Form++144++++++++BECTON+DICKINSON+%26amp%3B+CO+++++++++++++++Filed+by%3A+Feld+Michael/26982059.html si-local-file:///var/storage/secattach/20260826/26982059.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++BECTON+DICKINSON+%26amp%3B+CO+++++++++++++++Filed+by%3A+Feld+Michael/26982059.html Wed, 26 Aug 2026 16:18:00 -0400 BDX O.00000286 http://www.streetinsider.com/SEC+Filings/Form++144++++++++BECTON+DICKINSON+%26amp%3B+CO+++++++++++++++Filed+by%3A+Feld+Michael/26982059.html si-local-file:///var/storage/secattach/20260826/26982059.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++BECTON+DICKINSON+%26amp%3B+CO+++++++++++++++Filed+by%3A+Feld+Michael/26982059.html Wed, 26 Aug 2026 16:18:00 -0400 BDX O.00000286 http://www.streetinsider.com/Press+Releases/BD+to+Present+at+Wells+Fargo+21st+Annual+Healthcare+Conference/26981919.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nj.frakes" idsrc="xmltag.org" >FRANKLIN LAKES, N.J.</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- BD (<span value="NYSE:BDX" idsrc="xmltag.org" >Becton, Dickinson and Company</span>) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the Wells Fargo 21^st Annual Healthcare Conference on <chron>Wednesday, September 9, 2026</chron>, at <chron>9:30 a.m. Eastern Time</chron>.</p> <p>The live webcast of BD's presentation can be accessed from the BD investor relations website, <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4760176-1&amp;h=1653625946&amp;u=http%3A%2F%2Finvestors.bd.com%2F&amp;a=investors.bd.com" target="_blank" rel="nofollow">investors.bd.com</a>. A replay of the event will be available on the same webpage following its conclusion.</p><p><b>About BD</b><br />BD is one of the world's largest pure-play medical technology companies with a http://www.streetinsider.com/Press+Releases/BD+to+Present+at+Wells+Fargo+21st+Annual+Healthcare+Conference/26981919.html Wed, 26 Aug 2026 16:15:00 -0400 A.01615153 BDX O.00000286 O.01214331 http://www.streetinsider.com/Press+Releases/BD+to+Present+at+Wells+Fargo+21st+Annual+Healthcare+Conference/26981919.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nj.frakes" idsrc="xmltag.org" >FRANKLIN LAKES, N.J.</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- BD (<span value="NYSE:BDX" idsrc="xmltag.org" >Becton, Dickinson and Company</span>) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the Wells Fargo 21^st Annual Healthcare Conference on <chron>Wednesday, September 9, 2026</chron>, at <chron>9:30 a.m. Eastern Time</chron>.</p> <p>The live webcast of BD's presentation can be accessed from the BD investor relations website, <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4760176-1&amp;h=1653625946&amp;u=http%3A%2F%2Finvestors.bd.com%2F&amp;a=investors.bd.com" target="_blank" rel="nofollow">investors.bd.com</a>. A replay of the event will be available on the same webpage following its conclusion.</p><p><b>About BD</b><br />BD is one of the world's largest pure-play medical technology companies with a http://www.streetinsider.com/Press+Releases/BD+to+Present+at+Wells+Fargo+21st+Annual+Healthcare+Conference/26981919.html Wed, 26 Aug 2026 16:15:00 -0400 A.01615153 BDX O.00000286 O.01214331 http://www.streetinsider.com/Press+Releases/BD+to+Present+at+Wells+Fargo+21st+Annual+Healthcare+Conference/26981919.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nj.frakes" idsrc="xmltag.org" >FRANKLIN LAKES, N.J.</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- BD (<span value="NYSE:BDX" idsrc="xmltag.org" >Becton, Dickinson and Company</span>) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the Wells Fargo 21^st Annual Healthcare Conference on <chron>Wednesday, September 9, 2026</chron>, at <chron>9:30 a.m. Eastern Time</chron>.</p> <p>The live webcast of BD's presentation can be accessed from the BD investor relations website, <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4760176-1&amp;h=1653625946&amp;u=http%3A%2F%2Finvestors.bd.com%2F&amp;a=investors.bd.com" target="_blank" rel="nofollow">investors.bd.com</a>. A replay of the event will be available on the same webpage following its conclusion.</p><p><b>About BD</b><br />BD is one of the world's largest pure-play medical technology companies with a http://www.streetinsider.com/Press+Releases/BD+to+Present+at+Wells+Fargo+21st+Annual+Healthcare+Conference/26981919.html Wed, 26 Aug 2026 16:15:00 -0400 A.01615153 BDX O.00000286 O.01214331 http://www.streetinsider.com/Press+Releases/BD+to+Present+at+Wells+Fargo+21st+Annual+Healthcare+Conference/26981919.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nj.frakes" idsrc="xmltag.org" >FRANKLIN LAKES, N.J.</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- BD (<span value="NYSE:BDX" idsrc="xmltag.org" >Becton, Dickinson and Company</span>) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the Wells Fargo 21^st Annual Healthcare Conference on <chron>Wednesday, September 9, 2026</chron>, at <chron>9:30 a.m. Eastern Time</chron>.</p> <p>The live webcast of BD's presentation can be accessed from the BD investor relations website, <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4760176-1&amp;h=1653625946&amp;u=http%3A%2F%2Finvestors.bd.com%2F&amp;a=investors.bd.com" target="_blank" rel="nofollow">investors.bd.com</a>. A replay of the event will be available on the same webpage following its conclusion.</p><p><b>About BD</b><br />BD is one of the world's largest pure-play medical technology companies with a http://www.streetinsider.com/Press+Releases/BD+to+Present+at+Wells+Fargo+21st+Annual+Healthcare+Conference/26981919.html Wed, 26 Aug 2026 16:15:00 -0400 A.01615153 BDX O.00000286 O.01214331 http://www.streetinsider.com/PRNewswire/BD+to+Present+at+Wells+Fargo+21st+Annual+Healthcare+Conference/26981919.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nj.frakes" idsrc="xmltag.org" >FRANKLIN LAKES, N.J.</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- BD (<span value="NYSE:BDX" idsrc="xmltag.org" >Becton, Dickinson and Company</span>) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the Wells Fargo 21^st Annual Healthcare Conference on <chron>Wednesday, September 9, 2026</chron>, at <chron>9:30 a.m. Eastern Time</chron>.</p> <p>The live webcast of BD's presentation can be accessed from the BD investor relations website, <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4760176-1&amp;h=1653625946&amp;u=http%3A%2F%2Finvestors.bd.com%2F&amp;a=investors.bd.com" target="_blank" rel="nofollow">investors.bd.com</a>. A replay of the event will be available on the same webpage following its conclusion.</p><p><b>About BD</b><br />BD is one of the world's largest pure-play medical technology companies with a http://www.streetinsider.com/PRNewswire/BD+to+Present+at+Wells+Fargo+21st+Annual+Healthcare+Conference/26981919.html Wed, 26 Aug 2026 16:15:00 -0400 A.01615153 BDX O.00000286 O.01214331 http://www.streetinsider.com/PRNewswire/BD+to+Present+at+Wells+Fargo+21st+Annual+Healthcare+Conference/26981919.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nj.frakes" idsrc="xmltag.org" >FRANKLIN LAKES, N.J.</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- BD (<span value="NYSE:BDX" idsrc="xmltag.org" >Becton, Dickinson and Company</span>) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the Wells Fargo 21^st Annual Healthcare Conference on <chron>Wednesday, September 9, 2026</chron>, at <chron>9:30 a.m. Eastern Time</chron>.</p> <p>The live webcast of BD's presentation can be accessed from the BD investor relations website, <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4760176-1&amp;h=1653625946&amp;u=http%3A%2F%2Finvestors.bd.com%2F&amp;a=investors.bd.com" target="_blank" rel="nofollow">investors.bd.com</a>. A replay of the event will be available on the same webpage following its conclusion.</p><p><b>About BD</b><br />BD is one of the world's largest pure-play medical technology companies with a http://www.streetinsider.com/PRNewswire/BD+to+Present+at+Wells+Fargo+21st+Annual+Healthcare+Conference/26981919.html Wed, 26 Aug 2026 16:15:00 -0400 A.01615153 BDX O.00000286 O.01214331 http://www.streetinsider.com/PRNewswire/BD+to+Present+at+Wells+Fargo+21st+Annual+Healthcare+Conference/26981919.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nj.frakes" idsrc="xmltag.org" >FRANKLIN LAKES, N.J.</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- BD (<span value="NYSE:BDX" idsrc="xmltag.org" >Becton, Dickinson and Company</span>) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the Wells Fargo 21^st Annual Healthcare Conference on <chron>Wednesday, September 9, 2026</chron>, at <chron>9:30 a.m. Eastern Time</chron>.</p> <p>The live webcast of BD's presentation can be accessed from the BD investor relations website, <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4760176-1&amp;h=1653625946&amp;u=http%3A%2F%2Finvestors.bd.com%2F&amp;a=investors.bd.com" target="_blank" rel="nofollow">investors.bd.com</a>. A replay of the event will be available on the same webpage following its conclusion.</p><p><b>About BD</b><br />BD is one of the world's largest pure-play medical technology companies with a http://www.streetinsider.com/PRNewswire/BD+to+Present+at+Wells+Fargo+21st+Annual+Healthcare+Conference/26981919.html Wed, 26 Aug 2026 16:15:00 -0400 A.01615153 BDX O.00000286 O.01214331 http://www.streetinsider.com/PRNewswire/BD+to+Present+at+Wells+Fargo+21st+Annual+Healthcare+Conference/26981919.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nj.frakes" idsrc="xmltag.org" >FRANKLIN LAKES, N.J.</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- BD (<span value="NYSE:BDX" idsrc="xmltag.org" >Becton, Dickinson and Company</span>) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the Wells Fargo 21^st Annual Healthcare Conference on <chron>Wednesday, September 9, 2026</chron>, at <chron>9:30 a.m. Eastern Time</chron>.</p> <p>The live webcast of BD's presentation can be accessed from the BD investor relations website, <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4760176-1&amp;h=1653625946&amp;u=http%3A%2F%2Finvestors.bd.com%2F&amp;a=investors.bd.com" target="_blank" rel="nofollow">investors.bd.com</a>. A replay of the event will be available on the same webpage following its conclusion.</p><p><b>About BD</b><br />BD is one of the world's largest pure-play medical technology companies with a http://www.streetinsider.com/PRNewswire/BD+to+Present+at+Wells+Fargo+21st+Annual+Healthcare+Conference/26981919.html Wed, 26 Aug 2026 16:15:00 -0400 A.01615153 BDX O.00000286 O.01214331